Access to private investments, which remains a differentiator for T. Rowe, is restricted in the ETF but is otherwise another avenue to gain an edge. This portfolio is unlikely to be flipped on its ...

They, however, formally include T. Rowe Price’s analyst stock ratings in their stock selection model, which is a change from Nanda, who mostly relied on analysts for biotechnology picks.